Rossari Biotech has announced the incorporation of a new subsidiary named Rossari (Singapore) Pte. Ltd. This strategic corporate development marks the company's expansion into the Singapore market through the establishment of an international subsidiary.

Corporate Structure Development

The creation of Rossari (Singapore) Pte. Ltd. represents a significant step in Rossari Biotech's organizational growth and international presence. This subsidiary structure will enable the company to establish operations in Singapore and potentially serve as a hub for broader regional activities.

Strategic Implications

The establishment of this Singapore-based subsidiary demonstrates Rossari Biotech's commitment to expanding its geographical footprint beyond domestic markets. Singapore's strategic location and business-friendly environment make it an attractive destination for companies looking to establish regional operations.

This corporate development reflects the company's growth strategy and its focus on building an international presence through structured subsidiary operations. The new entity will operate under the Rossari brand while maintaining its connection to the parent company's core business activities.

By incorporating Rossari (Singapore) Pte. Ltd., Rossari Biotech aims to strengthen its international presence and potentially explore new business opportunities in the Southeast Asian market. This move aligns with the company's broader strategy of expanding its global reach and enhancing its competitive position in the international marketplace.

Rossari Biotech Limited has successfully completed the incorporation of its wholly owned subsidiary in Singapore, marking the completion of a significant milestone in the company's global expansion strategy. The subsidiary, Rossari (Singapore) Pte. Ltd., was officially incorporated on December 18, 2025, following the earlier board approval for an initial investment of up to USD 10.00 million.

Incorporation Completion

The company has received confirmation of the successful incorporation through the incorporation certificate issued by the Accounting and Corporate Regulatory Authority (ACRA), Singapore. This development represents the execution of the board's earlier decision to establish a strategic presence in Singapore for global investment and expansion activities.

Investment and Structure Details

The key parameters of the completed Singapore subsidiary incorporation are outlined below:

The initial capital investment will be deployed through equity share capital subscription, with the company planning to utilize the funds in multiple tranches based on business requirements and expansion plans.

Strategic Implementation

The newly incorporated subsidiary will serve as a strategic entity for global investment and expansion activities. This establishment strengthens Rossari Biotech's international presence and provides access to new markets through the Singapore base, leveraging the city-state's business-friendly environment and strategic location for accessing broader Asian and global markets.

Regulatory Compliance and Communication

The incorporation completion has been communicated in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has informed both BSE Limited and National Stock Exchange of India Limited about this development.

The company has confirmed that all future transactions with the Singapore subsidiary will be conducted on an arms-length basis, ensuring transparency and regulatory compliance. This successful incorporation positions Rossari Biotech to leverage Singapore's strategic advantages in the specialty chemicals sector for its global expansion initiatives.